Ke Chen

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

D. Schadendorf, V. Sondak, P. Ascierto, 2022, The Lancet.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

A. Carneiro, G. Long, L. Ny, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer

X. Shao, Xiaojian Wang, Ke Chen, 2022, Technology in cancer research & treatment.

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

D. Schadendorf, M. Ross, P. Ascierto, 2022, European journal of cancer.

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

D. Schadendorf, V. Sondak, P. Ascierto, 2021, Annals of Oncology.

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review

Wei Wang, X. Shao, Xiaojian Wang, 2023, Technology in cancer research & treatment.

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

A. Carneiro, A. Arance, G. Long, 2021, Journal of Clinical Oncology.